Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

赛马鲁肽 医学 安慰剂 超重 中止 减肥 内科学 体质指数 随机对照试验 肥胖 不利影响 置信区间 重量变化 物理疗法 糖尿病 2型糖尿病 利拉鲁肽 内分泌学 替代医学 病理
作者
W. Timothy Garvey,Rachel L. Batterham,Meena Bhatta,Silvio Buscemi,Louise Christensen,Juan P. Frías,Esteban Jódar,Kristian Kandler,Georgia Rigas,Thomas A. Wadden,Sean Wharton,the STEP 5 Study Group
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:28 (10): 2083-2091 被引量:759
标识
DOI:10.1038/s41591-022-02026-4
摘要

Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg ( n = 152) or placebo ( n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m –2 and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group ( n = 152) versus −2.6% with placebo ( n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001). More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%). In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被李铮采纳,获得10
刚刚
刚刚
刚刚
桃桃完成签到 ,获得积分10
1秒前
1秒前
科研通AI65的应助被ZJ采纳,获得10
1秒前
搜集达人的应助被YunjiangZhang采纳,获得10
1秒前
1秒前
2秒前
2秒前
2秒前
酷酷班发布了新的文献求助10
3秒前
Porkpike完成签到,获得积分10
3秒前
4秒前
Ypearl发布了新的文献求助10
4秒前
4秒前
5秒前
xl完成签到,获得积分10
5秒前
5秒前
QLLW完成签到,获得积分10
6秒前
糖心发布了新的文献求助10
7秒前
哈哈发布了新的文献求助30
7秒前
一颗苹果发布了新的文献求助10
7秒前
7秒前
7秒前
NexusExplorer的应助被HJC采纳,获得10
7秒前
smile发布了新的文献求助10
7秒前
7秒前
Niko_Mak完成签到,获得积分10
8秒前
SHukie完成签到 ,获得积分10
8秒前
8秒前
8秒前
Ava的应助被俭朴钢铁侠采纳,获得10
9秒前
9秒前
祎辰完成签到 ,获得积分10
9秒前
9秒前
xh发布了新的文献求助20
9秒前
9秒前
Maestro_S的应助被科研通管家采纳,获得10
10秒前
YAMP完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482